Medullary Thyroid Carcinoma
Conditions
Brief summary
This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.
Interventions
OTHERNo treatment given
No treatment given
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years or older during the year of index (date of qualifying medication) * In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1 * ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period) * No evidence of cohort qualifying medication during 12-month before the index date * Reside in the US, including the District of Columbia (DC) during the study period * No missing values for year of birth
Exclusion criteria
* Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to first occurence of Medullary Thyroid Carcinoma (MTC) | From day 1 up to 15 years | Measured in number of days. |
Countries
United States
Contacts
STUDY_DIRECTORClinical Transparency (dept. 2834)
Novo Nordisk A/S
Outcome results
None listed